An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY1161909 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Empesertib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 10 Oct 2018 Status has been changed to discontinued.
- 29 Nov 2017 Status changed from active, no longer recruiting to completed.
- 30 May 2017 Planned End Date changed from 1 Apr 2017 to 21 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History